文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

生物信息学分析突出差异表达的 CCNB1 和 PLK1 基因作为潜在的抗乳腺癌药物靶点和预后标志物。

Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers.

机构信息

School of Biomedical Engineering, Dalian University of Technology, Dalian 116024, China.

School of Pharmacy, Binzhou Medical University, Yantai 264003, China.

出版信息

Genes (Basel). 2022 Apr 7;13(4):654. doi: 10.3390/genes13040654.

DOI:10.3390/genes13040654
PMID:35456460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9027215/
Abstract

Breast cancer is one of the most common malignant tumors in women worldwide. Early diagnosis, treatment, and prognosis of breast cancer are global challenges. Identification of valid predictive diagnosis and prognosis biomarkers and drug targets are crucial for breast cancer prevention. This study characterizes differentially expressed genes (DEGs) based on the TCGA database by using DESeq2, edgeR, and limma. A total of 2032 DEGs, including 1026 up-regulated genes and 1006 down-regulated genes were screened. Followed with WGCNA, PPI analysis, GEPIA 2, and HPA database verification, thirteen hub genes including , , , , , , , , , , , , , , and were obtained, and they may serve as potential therapeutic targets of breast cancer. Especially, overexpression of and are strongly associated with the low survival rate of breast cancer patients, demonstrating their potentiality as prognostic markers. Moreover, and are highly expressed in all breast cancer stages, suggesting that they could be further studied as potential drug targets. Taken together, our study highlights and as potential anti-breast cancer drug targets and prognostic markers.

摘要

乳腺癌是全球女性最常见的恶性肿瘤之一。乳腺癌的早期诊断、治疗和预后是全球性的挑战。鉴定有效的预测诊断和预后生物标志物及药物靶点对于乳腺癌的预防至关重要。本研究通过 DESeq2、edgeR 和 limma 基于 TCGA 数据库对差异表达基因（DEGs）进行了特征分析。共筛选出 2032 个 DEGs，包括 1026 个上调基因和 1006 个下调基因。通过 WGCNA、PPI 分析、GEPIA2 和 HPA 数据库验证，获得了 13 个枢纽基因，包括 、 、 、 、 、 、 、 、 、 、 、 ，它们可能作为乳腺癌的潜在治疗靶点。特别是， 和 的高表达与乳腺癌患者的低生存率密切相关，表明它们可能作为预后标志物。此外， 在所有乳腺癌分期中均高度表达，提示它们可能进一步作为潜在的药物靶点进行研究。综上所述，本研究强调 和 作为潜在的抗乳腺癌药物靶点和预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/b6afc138f8fc/genes-13-00654-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/7903fe5c7120/genes-13-00654-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/c5324db98eb6/genes-13-00654-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/4552cbe8b222/genes-13-00654-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/7823bd122425/genes-13-00654-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/3d00821e86e8/genes-13-00654-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/5280c3b1fe61/genes-13-00654-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/b6afc138f8fc/genes-13-00654-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/7903fe5c7120/genes-13-00654-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/c5324db98eb6/genes-13-00654-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/4552cbe8b222/genes-13-00654-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/7823bd122425/genes-13-00654-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/3d00821e86e8/genes-13-00654-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/5280c3b1fe61/genes-13-00654-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f254/9027215/b6afc138f8fc/genes-13-00654-g007.jpg

相似文献

[1]
Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers.

Genes (Basel). 2022-4-7

[2]
CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis.

BMC Med Genomics. 2019-12-23

[3]
Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.

Biomed Res Int. 2021

[4]
Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.

PLoS One. 2021

[5]
CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis.

Biomed Res Int. 2019-10-13

[6]
Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.

BMC Cancer. 2017-12-16

[7]
Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients.

Biomed Res Int. 2018-9-30

[8]
[CDK1, CCNB1 and NDC80 are associated with prognosis and progression of hepatitis B virus-associated hepatocellular carcinoma: a bioinformatic analysis].

Nan Fang Yi Ke Da Xue Xue Bao. 2021-10-20

[9]
Bioinformatical Analysis of Gene Expression Omnibus Database Associates TAF7/CCNB1, TAF7/CCNA2, and GTF2E2/CDC20 Pathways with Glioblastoma Development and Prognosis.

World Neurosurg. 2020-3-5

[10]
Identification of hub genes associated with bladder cancer using bioinformatic analyses.

Transl Cancer Res. 2022-5

引用本文的文献

[1]
An analysis of gene expression profiles through machine learning uncovers the new diagnostic signature for diabetic foot ulcers.

Front Genet. 2025-6-24

[2]
Multi-omics insights into the roles of CCNB1, PLK1, and HPSE in breast cancer progression: implications for prognosis and immunotherapy.

Discov Oncol. 2025-4-5

[3]
The Expression of Ferroptosis-Related Genes in Hepatocellular Carcinoma and Their Relationships With Prognosis.

J Hepatocell Carcinoma. 2025-3-20

[4]
Intratumoral microbiota, fatty acid metabolism, and tumor microenvironment constitute an unresolved trinity in colon adenocarcinoma.

Sci Rep. 2025-1-20

[5]
Roles of the CDCA gene family in breast carcinoma.

Sci Prog. 2025

[6]
Targeting CDK1 and copper homeostasis in breast cancer via a nanopolymer drug delivery system.

Cell Biol Toxicol. 2024-12-26

[7]
Only Infant -Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Int J Mol Sci. 2024-11-27

[8]
KIF18A promotes cervical squamous cell carcinoma progression by activating the PI3K/AKT pathway through upregulation of CENPE.

Cancer Biomark. 2024

[9]
Construction of a new prognostic model for colorectal cancer based on bulk RNA-seq combined with The Cancer Genome Atlas data.

Transl Cancer Res. 2024-6-30

[10]
Reversal of the tamoxifen‑resistant breast cancer malignant phenotype by proliferation inhibition with bromosulfonamidine amino‑podophyllotoxin.

Oncol Lett. 2024-6-13

本文引用的文献

[1]
TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination.

Cancer Cell Int. 2021-10-18

[2]
Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells and .

Dis Markers. 2021

[3]
Robustness of differential gene expression analysis of RNA-seq.

Comput Struct Biotechnol J. 2021-5-26

[4]
Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.

Breast Cancer Res Treat. 2021-1

[5]
Opposing Functions of BRD4 Isoforms in Breast Cancer.

Mol Cell. 2020-5-23

[6]
Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells.

PeerJ. 2020-4-28

[7]
BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation.

Oncol Lett. 2020-5

[8]
FOXK1, Regulated by miR-365-3p, Promotes Cell Growth and EMT Indicates Unfavorable Prognosis in Breast Cancer.

Onco Targets Ther. 2020-1-21

[9]
CDK1 in Breast Cancer: Implications for Theranostic Potential.

Anticancer Agents Med Chem. 2020

[10]
AURKB promotes gastric cancer progression via activation of expression.

Aging (Albany NY). 2020-1-25

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索